Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

NCT01719549 | Completed Phase 2

• 1 other identifier: AMC1202
• Study Type: interventional
• Target: 19
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center, prospective, single-arm, open-label phase II study

Conditions

Gastric Cancer

Keywords

Gastric Cancer; Dovitinib

Outcome Measures

Primary Outcomes (2)

• response rate

  To evaluate with abdominal and pelvic dynamic CT scan every 6 weeks using RECIST version 1.1

  1year

• Progression-free survival

  To evaluate progression-free survival (PFS) with TKI258(Dovitinib) administered orally at 500 mg/day on a 5 days on/2 days off dosing schedule to adult patients \> 18 years with evaluable metastatic or unresectable gastric cancer harboring FGFR2 amplification (copy number \> 3, identified by real time PCR using TaqMan probe) who failed one or two lines of chemotherapy in palliative setting.

  From date of enrollment to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years

Secondary Outcomes (3)

• Number of Adverse Events

  1year

• Evaluation of Efficacy

  From date of randomization to death from any cause, assessed up to 2 years

• FGFR2 copy number

  1year

Study Arms (1)

Dovitinib

EXPERIMENTAL

Drug: Dovitinib

Interventions

Dovitinib DRUG

* Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule * Study drug: TKI258 capsule * Dose: 500mg p.o. qd * Every 3 weeks

Also known as: TKI258

Dovitinib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Pathologically proven metastatic or unresectable adenocarcinoma of stomach or gastroesophageal junction
• Patients with progressive disease (radiological confirmation required) after one or two lines of chemotherapy in palliative setting for advanced gastric cancer. Adjuvant or neoadjuvant chemotherapy is not counted as one line of prior chemotherapy.
• FGFR2 amplification (copy number \> 3, identified by real time PCR using TaqMan probe) by prescreening or screening procedure. Prescreening can be performed with Real Time PCR for FGFR2 amplification any time during the prior chemotherapy. At least 18 patients should have 6 or more copy numbers of FGFR2 (see Statistical Methods and Data Analysis).
• Presence of at least one measurable disease (for co-primary endpoint of overall response rate in patients with FGFR2 copy number \> 6) or one evaluable disease (for co-primary endpoint of PFS in patients with FGFR2 copy number \> 3) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
• Age of 18 years or older
• Expected life expectancy of more than 3 months
• ECOG performance status 0\~2
• Resolution of all toxic effects of prior treatments to grade 0 or 1 by NCI-CTCAE version 4.0
• Adequate bone marrow, hepatic, renal, and other organ functions ( Neutrophil \> 1,500/mm3, Platelet \> 75,000/mm3, Hemoglobin \> 8.0 g/dL, Total bilirubin \< 1.5 x upper limit of normal (ULN), AST/ALT \< 2.5 x ULN (or \< 5 x ULM in case of liver metastases), Creatinine \< 1.5 x ULN, Amylase, lipase \< ULN, Electrolytes should be within normal limits.,Urine dipstick reading: Negative for proteinuria or, if documentation of +1 results for protein on dipstick reading, then total urinary protein 500 mg and measured creatinine clearance 50 mL/min/1.73m2 from a 24-hour urine collection)
• Women with reproductive potential must have a negative serum or urine pregnancy test; and men and women of reproductive potential must practice an effective method of avoiding pregnancy while receiving study drug.
• Washout period of previous chemotherapy for more than 4 times the half life or at least 2 weeks after completion of prior chemotherapy whichever comes first
• No prior FGF/FGFR inhibitor
• No prior radiation therapy within 2 weeks of the study (Irradiated lesions should not be included in the evaluable lesions.)
• Written informed consent

You may not qualify if:

• Past or concurrent history of neoplasm other than gastric adenocarcinoma, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri
• Bowel obstruction
• Evidence of serious gastrointestinal bleeding
• Women of child-bearing potential who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial in both sexes. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. Women of child-bearing potential, defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months), must have a negative serum pregnancy test 72 hours prior to starting TKI258.
• Clinically significant cardiac disease (New York Heart Association, Class III or IV) or impaired cardiac function or clinically significant cardiac diseases, including any one of the following:
• Uncontrolled infection
• Diabetes mellitus (insulin dependent or independent disease, requiring chronic medication) with signs of clinically significant peripheral vascular disease.
• Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two or more interventions/month.
• Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis,adrenal or thyroid glands.
• Prior acute or chronic pancreatitis of any etiology.
• Acute and chronic liver disease and all chronic liver impairment.
• Malabsorption syndrome or uncontrolled gastrointestinal toxicities (nausea, diarrhea,vomiting) with toxicity greater than NCI CTCAE grade 2.
• Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for this study.
• Treatment with any of the medications that have a potential risk of prolonging the QT interval or inducing Torsades de Points and the treatment cannot be discontinued or switched to a different medication prior to starting study drug.
• Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, rifampin, phenytoin and quinidine 2 weeks prior baseline.

Sponsors & Collaborators

• Asan Medical Center: lead
• Novartis: collaborator

Study Sites (1)

Asan Medical Center

Seoul, 138-736, South Korea

Location

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Officials

• Yoon-Koo Kang, PhD

  Asan Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: October 22, 2012
• First Posted: November 1, 2012
• Study Start: September 1, 2012
• Primary Completion: February 1, 2016
• Study Completion: November 1, 2016
• Last Updated: January 7, 2020

Record last verified: 2020-01

Locations

KR (1)